Atypische Neuroleptika und neue Antidepressiva in der Therapie neurologischer Erkrankungen

A. Bayas; J. Kornhuber; M. Naumann

doi:10.1055/s-2001-11300

Aktuelle Neurologie, Table of Contents

Aktuelle Neurologie 2001; 28(2): 62-73
DOI: 10.1055/s-2001-11300

ÜBERSICHT

Übersicht
© Georg Thieme Verlag Stuttgart · New York

Atypische Neuroleptika und neue Antidepressiva in der Therapie neurologischer Erkrankungen

A. Bayas¹ , J. Kornhuber² , M. Naumann¹

¹Neurologische Universitätsklinik Würzburg
²Psychiatrische Universitätsklinik Erlangen

Abstract

Zusammenfassung

Atypische Neuroleptika und neue Antidepressiva unterscheiden sich von den klassischen Präparaten durch unterschiedliche Wirkmechanismen und zum Teil günstigere Nebenwirkungsspektren. Wenngleich sie primär zur Therapie psychiatrischer Erkrankungen zum Einsatz kommen, führte vor allem dieses günstige Nebenwirkungsprofil zum Einsatz der Präparate auch bei neurologischen Erkrankungen, bei denen die Anwendung älterer Substanzen, wie trizyklische Antidepressiva, oft mit intolerablen Nebenwirkungen verbunden war. So wurden atypische Neuroleptika, wie Clozapin, erfolgreich zur Behandlung L-Dopa-induzierter Psychosen beim M. Parkinson eingesetzt, ohne extrapyramidale Symptome zu verschlechtern. Neue Antidepressiva, wie Fluoxetin, zeigten sich unter anderem bei der Behandlung der Affektinkontinenz als wirksam. Der vorliegende Artikel soll einen Überblick über den Einsatz atypischer Neuroleptika und neuer Antidepressiva (fokussiert auf die selektiven Serotoninwiederaufnahmehemmer) zur Behandlung neurologischer Krankheiten geben.

Atypical Neuroleptics and New Antidepressants in the Treatment of Neurological Disorders

Compared to the classical drugs, atypical neuroleptics and new antidepressants are characterised by different mechanisms of action and, in a number of aspects, by a more favourable side effect profile. Though primarily applied in psychiatric disorders these properties prompted their use in neurological diseases, where side effects of classical therapeutics, such as tricyclic antidepressants, are often a major concern. For example, atypical neuroleptics, like clozapine, were successfully applied for the treatment of l-dopa-induced psychosis in Parkinson's disease without deterioration of motor functions. New antidepressants, like fluoxetine, have been shown to be effective in emotionalism. This article provides an overview of the use of atypical neuroleptics and new antidepressants (focused on selective serotonin reuptake inhibitors) in the treatment of neurological disorders.

Full Text

References

Literatur

1 Riedel M, Müller N, Möller H-J. Atypische Neuroleptika. Akt Neurol. 2000; 27 340-348
2 Scholz E, Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci. 1985; 235 60-64
3 Greene P, Coté L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol. 1993; 60 703-706
4 Koller W C, Pahwa R, Lyons K, Smith D. Low dose clozapine in the treatment of levodopa induced psychosis (abstract). Mov Disord. 1994; 9 64
5 Rabey JM,Trevas T A, Orlov E. et al . Low dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology. 1995; 45 432-434
6 Factor S A, Molho E S, Podskalny G D, Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol. 1995; 65 115-138
7 Factor S A, Friedman J H. The emerging role of clozapine in the treatment of movement disorders. Mov Disord. 1997; 12 483-496
8 Retz W, Rösler M, Sitzmann L, Becker T. Clozapin in der Behandlung neuropsychiatrischer Erkrankungen im Alter. Fortschr Neurol Psychiatrie. 1997; 65 347-353
9 Trosch R T, Friedman J H, Lannon M C. et al . Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience. Mov Disord. 1998; 13 377-382
10 Wolters E C. Dopaminomimetic psychosis in Parkinson's disease patients. Neurology. 1999; 52 S10-13
11 The French Clozapine Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet. 1999; 353 2041-2042
12 The Parkinson study group. Low dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999; 340 757-763
13 Wolters E C, Hurwitz T A, Mak E. et al . Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology. 1990; 40 832-834
14 Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand. 1986; 73 295-297
15 Fischer P A, Baas H, Hefner R. Treatment of parkinsonian tremor with clozapine. J Neural Trans. 1990; 2 223-228
16 Friedman J H, Lannon M C. Clozapine-responsive tremor in Parkinson's disease. Mov Disord. 1990; 5 225-265
17 Bonucelli U, Ceravolo R, Salvetti S. et al . Clozapine in Parkinson's disease tremor. Effect of acute and chronic administration. Neurology. 1997; 49 1587-1590
18 McCarthy R H. Clozapine reduces essential tremor independent of its antipsychotic effect. A case report. J Clin Pharmacol. 1994; 12 212-213
19 Ceravolo R, Salvetti S, Piccini P. Acute and chronic effects of clozapine in essential tremor. Mov Disord. 1999; 14 468-472
20 Delecluse F, Elosegi J A, Gérard J. A case of tardive tremor sucessfully treated with clozapine. Mov Disord. 1998; 13 846
21 Miller C H, Mohr F, Umbricht D. et al . The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry. 1998; 59 69-75
22 Kane J, Honigsfeld G, Singer J. et al . Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry. 1988; 45 789-796
23 Lieberman J A, Saltz B L, Johns C A. et al . The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991; 158 503-510
24 Tamminga C A, Thaker G K, Moran M. et al . Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry. 1994; 55 102-106
25 Bonucelli U, Ceravolo R, Maremmani C. et al . Clozapine in Huntington's disease. Neurology. 1994; 44 821-823
26 van Vugt J PP, Siesling S, Vergeer M. et al . Clozapine versus placebo in Huntington's disease (abstract). Mov Disord. 1996; 11 54
27 Benett J P, Landow E R, Schuh L A. Suppression of dyskinesias in advanced Parkinson's disease. Neurology. 1993; 43 1551-1555
28 Caine E D, Jolinsky R J, Kartzinel J. et al . The trial use of clozapine for abnormal involuntary movement disorder. Am J Psychiatry. 1979; 136 317-320
29 Thiel A, Dressler D, Kistel C, Rüther E. Clozapine treatment of spasmodic torticollis. Neurology. 1994; 44 957-958
30 Miller D D, Sharafuddin M JA, Kathol R G. A case of clozapine induced neurolpetic malignant syndrome. J Clin Psychiatry. 1991; 52 99-101
31 Beasley C M, Tollefson G D, Tran P V. et al . Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996; 14 111-123
32 Tran P V, Dellva M A, Tollefson G D. et al . Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry. 1997; 58 205-211
33 Wolters E C, Jansen E NH, Tuynman-Qua H G, Bergmans B ML. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 1996; 47 1085-1087
34 Aarsland D, Larsen J P, Lim N G, Tandberg E. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J Neuropsychiatry Clin Neurosci. 1999; 11 392-394
35 Walker Z, Grace J, Overshot R. et al . Olanzapine in dementia with lewy bodies: a clinial study. Int J Geriatr Psychiatry. 1999; 14 459-466
36 Graham J, Sussman J D, Ford K S, Sagar H J. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. J Neurol Neurosurg Psychiatry. 1998; 65 774-777
37 Friedmann J. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease (letter). Neurology. 1998; 50 1195-1196
38 Jiménez-Jiménez F J, Tallón-Barranco A, Orti-Parejy M. et al . Olanzapine can worsen parkinsonism. Neurology. 1998; 50 1183-1184
39 Friedman J H, Goldstein S, Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. Clin Neuropharmacol. 1998; 21 285-288
40 Molho E S, Factor S A. Worsening of motor features of parkinsonism with olanzapine. Mov Disord. 1999; 14 1014
41 Strauss A J, Bailey R K, Dralle P W. et al . Conventional psychotropic-induced tremor extinguished by olanzapine (letter). Am J Psychiatry. 1998; 155 1132
42 Soutullo C, Keck P, McElroy S. Olanzapine in the treatment of tardive dyskinesia. A report of two cases. J Clin Psychopharmacol. 1999; 19 100-101
43 Fulton B, Goa K L. Olanzapine. A review of ist pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1997; 53 281-298
44 Filice G A, McDougall B C, Ercan-Fang N, Billington C. Neuroleptic malignant syndrome associated with olanzapine. Ann Pharmacother. 1998; 32 1158-1159
45 Chouinard G, Jones B, Remington G. et al . A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophenic patients. J Clin Psychopharmacol. 1993; 13 25-40
46 Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double blind, parallel group study versus haloperidol. Br J Psychiatry. 1995; 166 712-726
47 Gwinn K A, Caviness J N. Risperidone-induced tardive dyskinesia and Parkinsonism. Mov Disord. 1997; 12 119-121
48 Addington D E, Toews J A, Addington J M. Risperidone and tardive dyskinesia: a case report. J Clin Psychiatry. 1995; 56 484-485
49 Friedman J H, Ott B. Should Risperidone be used in Parkinson's disease?. J Neuropsychiatry Clin Neurosci. 1998; 10 473-474
50 Meco G, Allesandri A, Bonifati V, Giustini P. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet. 1994; 343 1370-1371
51 Workman R H, Orengo C, Bakey A. et al . The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1997; 9 594-597
52 Meco G, Alessandri A, Giustini P, Bonifati V. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label long-term study. Mov Disord. 1997; 12 610-612
53 Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease (letter). Lancet. 1994; 344 681
54 Rich S, Fridman J H, Ott B. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry. 1995; 56 556-559
55 McKeith I G, Ballard C G, Harrison R WS. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet. 1995; 346 699
56 Allen R L, Walker Z, D'Ath P J, Katona C LE. Risperidone for psychotic and behavioural problems in Lewy body dementia (letter). Lancet. 1995; 346 185
57 Geizer M, Ancill R J. Combination of risperidone and donazepil in Lewy body dementia. Can J Psychiatry. 1998; 43 421-422
58 van der L inden, Bruggeman R, van Woerkom T. Risperidone in the treatment of Gille de la Tourette's syndrome (abstract). Ann Neurol. 1993; 34 263
59 Shulman L, Singer C, Weiner W. Risperidone in Gilles de la Tourette syndrome. Neurology. 1995; 45 1419
60 Bruun R D, Budman C L. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry. 1996; 57 29-31
61 Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol. 1995; 15 36S-44S
62 Evidente V, Gwinn-Hardy K, Caviness J. Risperidone is effective in severe hemichorea/hemiballism. Mov Disord. 1999; 14 377-379
63 Meco G, Bonifati V, Alessandri A. et al . Risperidone in Huntington's diesease (letter). Human Psychopharmacol. 1995; 10 353-354
64 Reveley M A, Dursum S M, Andrews H A. Comparative use of sulpirid and risperidone in Huntington's disease: a pilot study. J Psychopharmacol. 1996; 10 162-165
65 Zuddas A, Cianchetti C. Efficacy of risperidone in idiopathic segmental dystonia (letter). Lancet. 1996; 347 127-128
66 Dave M. Two cases of risperidone-induced neuroleptic malignant syndrome. Am J Psychiatry. 1995; 152 1233-1244
67 Bajjoka I. Risperidone-induced neuroleptic malignant syndrome. Ann Emerg Med. 1997; 30 698-700
68 Luckhaus C, Müller W. Quetiapin, ein neues atypisches Neuroloptikum. Psychopharmakotherapie. 2000; 2 63-69
69 Fernandez H H, Friedmann J H, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in parkinson's disease. Mov Disord. 1999; 14 484-487
70 Friedmann J H, Steward A F. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 2000; 15 201-211
71 Fagius J, Osterman P O, Sidén Å, Wiholm B-E. Guillain-Barré syndrome following zimeldine treatment. J Neurol Neurosurg Psychiatry. 1985; 48 65-69
72 Songer D A, Schulte H. Venlafaxine for the treatment of chronic pain (letter). Am J Psychiatry. 1996; 153 737
73 Taylor K, Rowbotham M C. Venlafaxine hydrochloride and chronic pain. WJM. 1996; 165 147-148
74 Brannon G E, Stone K D. The use of mirtazapine in a patient with chronic pain. J Pain Symptom Manage. 1999; 18 382-385
75 Davis J L, Smith R L. Painful peripheral diabetic neuropathy treated with venlafaxine HCl extended release capsules (letter). Diabetes care. 1999; 22 1909-1910
76 Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology. 1999; 53 1154
77 Mirzaian E, Gastpar M. Neue Antidepressiva. Akt Neurol. 2000; 27 132-137
78 Robinson R G. Treatment issues in poststroke depression. Depression and anxiety. 1998; 8, Suppl 1 85-90
79 Teasell R W, Merskey H, Deshpande S. Antidepressants in rehabilitation. Phys Med Rehabil Clin N Am. 1999; 10 237-253
80 Ramasubbu R, Flint A, Brown G. et al . Diminished serotonin-mediated prolactin responses in nondepressed stroke patients compared with healthy normal subjects. Stroke. 1998; 29 1293-1298
81 Stamenkovic M, Schindler S, Kasper S. Therapie der Poststroke-Depression mit Fluoxetin. Nervenarzt. 1996; 67 62-67
82 Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke. 1994; 25 1099-1104
83 Dam M, Tonin P, De Boni A. et al . Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996; 27 1211-1214
84 Robinson R G, Schultz S K, Castillo C. et al . Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000; 157 351-359
85 Wiart L, Petit H, Joseph P A. et al . Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke. 2000; 31 1829-1832
86 Andersen G. Treatment of uncontrolled crying after stroke. Drugs Aging. 1995; 6 105-111
87 Andersen G, Vestergaard K, O Riis J. Citalopram for post-stroke pathological crying. Lancet. 1993; 342 837-839
88 Brown K W, Sloan R L, Pentland B. Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatr Scand. 1998; 98 455-458
89 Burns A, Russell E, Stratton-Powell H. et al . Sertraline in stroke-associated lability of mood. Int J Geriat Psychiatry. 1999; 14 681-685
90 Müller U, Murai T, Bauer-Wittmund T, von Cramon D Y. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj. 1999; 13 805-811
91 Hanger H C. Emotionalism after stroke (letter). Lancet. 1993; 342 1235-1236
92 Iannaccone S, Ferini-Strambi L. Pharmacological treatment of emotional lability. Clin Neuropharmacol. 1996; 19 532-535
93 Seliger G M, Hornstein A, Flax J. et al . Fluoxetine improves emotional incontinence. Brain injury. 1992; 6 267-270
94 Derex L, Ostrowsky K. Severe pathological crying after left anterior choroidal artery infarct. Reversibility with paroxetine treatment. Stroke. 1997; 28 1464-1466
95 Nahas Z, Arlinghaus K A, Kotrla K J. et al . Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J Neuropsy Clin Neurosci. 1998; 10 453-455
96 Schachter M, Parkes J D. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry. 1980; 43 171-174
97 Langdon N, Shindler J, Parkes J D, Bandak S. Fluoxetine in the treatment of cataplexy (letter). Sleep. 1986; 9 371-373
98 Frey J, Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology. 1994; 44 707-709
99 Sindrup S H, Bjerre U, Dejgaard A. et al . The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992; 52 547-552
100 Sindrup S H, Gram L F, Brosen K. et al . The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990; 42 135-144
101 Sindrup S H, Grodum E, Gram L F, Beck-Nielsen H. Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study. Ther Drug Monit. 1991; 13 408-414
102 Max M B, Lynch S A, Muir J. et al . Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. New Engl J Med. 1992; 326 1250-1256
103 Goodnick P J, Jimenez I, Kumar A. Sertraline in diabetic neuropathy: preliminary results. Ann Clin Psychiatry. 1997; 9 255-257
104 Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache. 1992; 32 101-104
105 Bank J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache. 1994; 34 476-478
106 Saper J R, Silberstein S D, Lake A E, Winters M E. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache. 1994; 34 497-502
107 Manna V, Bolino F, Di Cicco L. Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserin. Headache. 1994; 34 44-49
108 Langemark M, Olesen J. Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial. Headache. 1994; 34 20-24
109 Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996; 61 285-290
110 Goldenberg D, Mayskiy M, Mossey C. et al . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996; 39 1852-1859
111 Wolfe F, Cathey M A, Hawley D J. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol. 1994; 23 255-259
112 Nørregaard J, Volkmann H, Danneskiold-Samsøe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995; 61 445-449
113 Smith A J. The analgesic effects of selective serotonin reuptake inhibitors. J Psychopharmacol. 1998; 12 407-413
114 Rani P U, Naidu M UR, Prasad V BN. et al . An evaluation of antidepressants in rheumatic pain conditions. Anesth Analg. 1996; 83 371-375
115 Scatton B, Javoy-Agid F, Rouquier L. et al . Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 1983; 275 321-328
116 Mayeux R, Stern Y, Cote L, Williams J BW. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology. 1984; 34 642-646
117 Richard I H, Kurlan R, and the Parkinson Study Group. A survey of antidepressant drug use in Parkinson's disease. Neurology. 1997; 49 1168-1170
118 Chase T N, Ng L KY, Watanabe A M. Parkinson's disease. Modification by 5-hydroxytryptophan. Neurology. 1972; 22 479-484
119 Valldeoriola F, Nobbe F A, Tolosa E. Treatment of behavioural disturbances in Parkinson's disease. J Neural Transm. 1997; 51, Suppl 175-204
120 Poewe W, Luginger E. Depression in Parkinson's disease. Impediments to recognition and treatment options. Neurology. 1999; 52 S2-S6
121 Cummings J L, Masterman D L. Depression in patients with Parkinson's disease. Int J Geriat Psychiatry. 1999; 14 711-718
122 McCance-Katz E F, Marek K L, Price L H. Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology. 1992; 42 1813-1814
123 Hauser R A, Zesiewicz T A. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord. 1997; 12 756-759
124 Meara J, Hobson P. Sertraline for the treatment of depression in Parkinson's disease (letter). Mov Disord. 1998; 13 622
125 Grubb B P, Samoil D, Kosinski D. et al . Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension. Am J Med. 1994; 97 366-368
126 Montastruc J L, Pelat M, Verwaerde P. et al . Fluoxetine in orthostatic hypotension of Parkinson's disease: a clinical and experimental pilot study. Fundam Clin Pharmacol. 1998; 12 398-402
127 Durif F, Vidailhet M, Bonnet A M. et al . Levodopa-induced dyskinesias are improved by fluoxetine. Neurology. 1995; 45 1855-1858
128 Montastruc J-L, Fabre N, Blin O. et al . Does fluoxetine aggravate Parkinson's disease? A pilot prospective study. Mov Disord. 1995; 10 355-357
129 Caley C F, Friedman J H. Does fluoxetine exacerbate Parkinson's disease?. J Clin Psychiatry. 1992; 53 278-282
130 Leo R J. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996; 57 449-454
131 Bouchard R H, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects (letter). Am J Psychiatry. 1989; 146 1352-1353
132 Richard I H, Maughn A, Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Mov Disord. 1999; 14 155-157
133 Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991; 148 705-713
134 Toyama S C, Iacono R P. Is it safe to combine a selective serotonin reuptake inhibitor with selegeline (letter)?. Ann Pharmacother. 1994; 28 405-406
135 Kasper S, Möller H-J, Müller-Spahn F. Depression: Diagnose und Pharmakotherapie. Stuttgart, New York; Thieme 1997
136 Nelson J G. Safety and tolerability of the new antidepressants. J Clin Psychiatry. 1997; 58, Suppl 6 26-31
137 Edwards J G, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs. 1999; 57 507-533
138 Caley C F. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother. 1997; 31 1481-1489
139 Gerber P E, Lynd L D. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998; 32 692-698
140 Lane R M. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol. 1998; 12 192-214

PD Dr. Markus Naumann

Neurologische Universitätsklinik der Bayerischen Julius-Maximilians-Universität Würzburg

Josef-Schneider-Str. 11

97080 Würzburg

Email: naumann@mail.uni-wuerzburg.de